57 results about "Cell Self Renewal" patented technology

Human breast tumors contain hetrogeneous cancer cells. using an animal xenograft model in which human breast cancer cells were grown in immunocompromised mice we found that only a small minority of breast cancer cells had capacity to form new tumors. The ability to form new tumors was not a slochastic property, rather certain populations of cancer cells were depleted for the ability to form new tumors, while other populations were enriched for the ability to form new tumors. Tumorigenic cells could be distinguished from non-tumorigenic cancer cells based on surface marker expression. We prospectively identified and isolated the tumorigenic cells as CD44³⁰CD24^−/lowLINEAGE A few as 100 cells from this population were able to form tumors the animal xenograft model, while tens of thousands of cells from non-tumorigenic populations failed to form tumors. The tumorigenic cells could be serially passaged, each time generating new tumors containing and expanded numbers of CD44^+CD24 Lineage tumorigenic cells as well as phenotypically mixed populations of non-tumorigenic cancer cells. This is reminiscent of the ability of normal stem cells to self-renew and differentiate. The expression of potential therapeutic targets also differed between the tumorigenic and non-tumorigenic populations. Notch activation promoted the survival of the tumorigenic cells, and a blocking antibody against Notch 4 induced tumorigenic breast cancer cells to undergo apoptosis.

Compositions and methods for the treatment of bone diseases, bone fractures, bone injuries and other bone abnormalities involving the use of Dkk protein, a Wnt antagonist, a Wnt inhibitor, or any other related protein for the stimulation or enhancement of mineralization and for stimulating the renewal of cells. One Dkk protein, Dickkopf-2 (Dkk-2), acts to stimulate bone formation independently of Wnt proteins which may be inhibited and/or antagonized by Dkk-2. Dkk-2 displayed enhanced specific targeting ability and enhanced biological activity in stimulating or enhancing mineralization. Dkk-2 also played a role in the differentiation and self-renewal of hematopoietic stem cells and mesenchymal stem cells, particularly in osteoblastogenesis and osteoclastogenesis.

Acute myeloid leukemia stem cells (AMLSC) are identified. The cells can be prospectively isolated or identified from patient samples, and are shown to possess the unique properties of cancer stem cells in functional assays for cancer stem cell self-renewal and differentiation, and in cancer diagnosis.

The present invention relates to 1,5-dihydro-2H-pyrrol-2-one compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells, including inducing the stem/progenitor cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into tissue cells.

The present invention relates to compositions and methods of inducing the self-renewal of stem/progenitor supporting cells, including inducing the stem/progenitor cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into hair cells.

A set of markers for melanoma cancer stem cells are provided. The cells can be prospectively isolated or identified from primary tumor samples, and possess the unique properties of cancer stem cells in functional assays for tumor initiation, cancer stem cell self-renewal and differentiation. In addition, cancer stem cells can be used as a predictor for disease progression. The CSC have the phenotype of being positive for expression CD271.

The invention belongs to the field of pharmacy, and relates to an application of a TCM monomer of apigenin to prepare a medicine for treating the pancreatic cancer. A CCK-8 method for evaluation, repeated screening and optimization, and a pharmacodynamic test for inhibiting proliferation of pancreatic cancer SW1990 cells are adopted to screen an effective monomer, having a strong anti-tumor effect, of apigenin. Moreover, an equipment of apigenin for interfering a Sonic Hedgehog signal channel of human pancreatic cancer SW1990 stem cells is carried out. The result shows that apigenin can obviously inhibit proliferation of pancreatic cancer stem cells, lower the ratio of pancreatic cancer stem cells, and reduce self-renewable ability of pancreatic cancer stem cells. The ratio of CD24+CD44+ cells is obviously lowered through flow cytometry; the amount of cancer stem cells cultured free of serum decreases; and expression of members in the Sonic Hedgehog signal channel at mRNA and protein levels is obviously lowered. The TCM monomer of apigenin can be taken as an individual unique active component for preparing the medicine for treating the pancreatic cancer.

The present invention relates to compositions and methods of inducing the self-renewal of stem/progenitor supporting cells, including inducing the stem/progenitor cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into hair cells.

The invention belongs to the field of pharmacy and relates to application of baicalein as an SHH (Sonic Hedgehog) signaling pathway inhibitor in the preparation of drugs for treating pancreatic cancer; results of animal experiments show that baicalein regulates Sonic Hedgehog signaling pathway to inhibit the proliferation of pancreatic cancer cells, induce apoptosis, and inhibit self-update of pancreatic cancer stem cells; the baicalein down-regulates IC50 of PANC-1 pancreatic cancer cells, weakening the in-vitro motor ability of the cells; the baicalein down-regulates the activity of CD44+/CD24+PANC-1 pancreatic cancer cells and down-regulates surface marker CD24 and CD44 protein expression for pancreatic cancer cells, thereby reducing nuclear transcription factor OCT-4 and SOX-2 protein-level expression, inhibiting SHH, PTCH-1, SMO and GLI2, and reducing OCT-4 and SOX-2 protein-level expression. The baicalein may act as an SHH signaling pathway inhibitor to prepare drugs for treating pancreatic cancer.

The invention relates to a method and a reagent for regulation and control of germ layer differentiation of an embryonic stem cell and an early embryo. The invention first reveals that activation of a Calcinuerin-NFAT signal path is closely related embryonic stem (ES) cell differentiation or self-renewal, wherein ES cell germ layer differentiation can be initiated through activation of the Calcinuerin-NFAT signal path, and ES cell self-renewal can be maintained for a long time through inhibition of the Calcinuerin-NFAT signal path.

The invention provides a method for inducing self-renewal of mammary stem cells. The invention discloses a new application of microRNA31. Experiments show that through over-expression of microRNA31, the proportion of mammary stem cells is obviously regulated up, clone formation ability is enhanced and therefore the self-renewal of the mammary stem cells is promoted.

The present invention relates to compositions and methods of inducing the self-renewal of stem/progenitor supporting cells, including inducing the stem/progenitor cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into hair cells.

The invention discloses a method for inducing transdifferentiation of mesenchymal stem cells (AD-MSCs) into skin stem cells (AD-SSCs). The method specifically comprises: S1, rapidly separating and purifying homogeneous adipose mesenchymal stem cells; S2, selecting a variety of small RNA molecules stem capable of being used for stem cell epigenetic regulation; S3, assembling and transfecting nucleic acid polypeptide nanoparticles; S4, preparing a culture medium for inducing transdifferentiation of mesenchymal stem cells into skin stem cells; and S5, activating a variety of related genes for guiding the self-renewing and the transdifferentiation of the skin stem cells. According to the present invention, the human adipose mesenchymal stem cells with characteristics of easy obtaining, abundant source, no moral and ethical issue, safty and effectiveness are used as the induced object and are subjected to large-scale, rapid and high-purity transdifferentiation by transfecting the two small RNAs molecules under the effect of the special serum-free culture medium to obtain the AD-SSCs, wherein the induced skin stem cells are the same as the skin stem cells naturally produced in human body, and have the self-renewing ability and the potential for differentiation into the skin cells.

Binding of the transcriptional co-activator, YAP1, to the transcription factor Oct4, induces Sox2, which is a transcription actor necessary for the self-renewal of stem-like cells from non-small celllung cancer. The WW domain of YAP1 binds to the PPxY motif of Oct4 to induce Sox2. Delivering a peptide corresponding to the WW domain could prevent the induction of Sox2 and stemness. Similarly, peptides and mimetics of the PPxY motif would be able to inhibit stemness. Disclosed are compounds that affect the Yap1:Oct4 interaction.

The invention discloses an application method of small molecules capable of promoting self-status-renewal of embryonic stem cells. The application method of the small molecules capable of promoting self-status-renewal of the embryonic stem cells comprises the following steps: passaging and culturing human and mouse embryonic stem cells under small molecular state of the method; and then, observingand detecting self-renewal state of the cells according to the method. Being added with CID755673 small molecules, the application method of the small molecules capable of promoting self-status-renewal of embryonic stem cells can solve the problems of liable state differentiation, complex passages operation, high culture-condition cost, unfavorable follow-up mechanism research and so on of humanand mouse embryonic stem cells under existing traditional cultivation conditions; moreover, the application method of the small molecules capable of promoting self-status-renewal of embryonic stem cells has the advantages of being stable in effects, economical, highly efficient, easy to operate, convenient to study and so on. In addition, clues are further provided for improving and establishing culture conditions of pluripotent stem cells of other species and genera; and thus, the application method of the small molecules capable of promoting self-status-renewal of embryonic stem cells playsan active role in promoting smooth development of basic and applied research of stem cells in the future.

Self renewal of pluripotent cells in culture is promoted using a combination of an activator of a signalling pathway downstream of a receptor of the TGF-beta superfamily and an activator of a gp130 downstream signalling pathway.